Table 2.
Main clinical and microbiological characteristics and outcomes.
| Overall (76) | Intensive PK Study (n = 41) | ||||
|---|---|---|---|---|---|
| Group 0 (n = 17) | Group 1 (n = 9) | Group 2 (n = 13) | Group 3 (n = 2) | ||
| Type of infection (n, (%)) | ABSSSIs: 16 [21] LVAD: 3 [4] Endocarditis: 3 [4] OAs: 54 [71] Osteomyelitis: 13 [25] Spondylodiscitis: 8 [15] Septic arthritis: 5 [11] PJI: 27 [49] |
ABSSSIs: 7 LVAD: 2 Septic Arthritis: 1 Osteomyelitis: 2 Prosthetic infection: 5 |
Septic arthritis: 1 Osteomyelitis: 4 Spondylodiscitis: 3 Endocarditis: 1 |
ABSSSIs: 2 Septic arthritis: 1 Osteomyelitis: 3 Spondylodiscitis: 2 PJI: 5 |
Spondylodiscitis: 1 PJI: 1 |
| Aetiology (n, (%)) | MSSA: 32 [42] MRSA 23 [30] MRSE 7 [9.2] MSSE 2 [2.6] S. Lugdunensis 1 [1.3] Streptococcus spp.: 3 [4.1] |
MRSA: 4 MSSA: 8 MRSE: 3 |
MRSA: 3 MSSA: 3 MRSE: 1 S. dysgalactiae: 1 |
MSSA: 8 MRSA: 4 MSSE: 1 |
MRSA: 2 |
| Outcome: cure (n, (%)) | 58/71 [82%] | 14/17 [82] | 9/9 [100] | 7/13 [54] | 2/2 [100] |
| Time to cure (days) | 28 [28–56] | 14 [14–56] | 84 [49–105] | 84 [84–112] | 28 [28–84] |